NYSE$TEVA
Teva Pharmaceutical Industries ADR · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Teva reported strong revenue growth driven by generics and AUSTEDO, and raised its 2024 financial guidance.
Teva's Q2 2024 revenues reached $4.2 billion, a 7% increase in U.S. dollars or 11% in local currency, driven by generics and innovative businesses. AUSTEDO grew 32% in the U.S. The company is raising its financial guidance for 2024.
- Global revenues increased by 7% to $4.2 billion, or 11% in local currency.
- AUSTEDO revenues in the U.S. increased by 32%.
- Non-GAAP diluted earnings per share increased to $0.61, compared to $0.56 in the second quarter of 2023.
- The company raised its financial guidance for 2024.
Headline financials
Revenue & EPS history
Teva · Revenue · Quarterly
$4.16B
Revenue by segment
Teva · $1.85B total across 3 segments · Q3 2023
- Europe$1.15B+7.2%62.0%
- International Markets$485M+2.1%26.2%
- Other Activities$217M—11.7%
Forward guidance
Teva is raising its financial guidance for 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.3%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
51%
38 / 74 earnings
Positive
+27.1%
Q2 2022
Best reaction
-34.1%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.9% | +11.7% | |
| Q4 2025 | +2.1% | +9.2% | +4.1% | |
| Q3 2025 | +20.4% | +18.6% | +39.1% | |
| Q2 2025 | +1.8% | -5.1% | +11.1% | |
| Q1 2025 | +8.9% | +11.4% | +10.2% | |
| Q4 2024 | -13.9% | -19.4% | -23.5% | |
| Q3 2024 | -6.8% | -7.5% | -7.7% | |
| Q2 2024 | +6.9% | +1.6% | +15.0% | |
| Q1 2024 | +14.7% | +21.0% | +20.6% | |
| Q4 2023 | +6.2% | +5.5% | +15.1% | |
| Q3 2023 | -3.0% | -2.4% | +8.6% | |
| Q2 2023 | +15.4% | +16.2% | +18.7% | |
| Q1 2023 | -9.8% | -11.3% | -19.5% | |
| Q4 2022 | -9.8% | -5.4% | -16.3% | |
| Q3 2022 | -3.3% | +3.7% | -1.1% | |
| Q2 2022 | +27.1% | +30.5% | +37.6% | |
| Q1 2022 | -2.3% | -8.1% | +11.6% | |
| Q4 2021 | +6.3% | +2.8% | -9.8% | |
| Q3 2021 | -7.0% | -1.7% | -9.6% | |
| Q2 2021 | +8.6% | +10.4% | +4.8% | |
| Q1 2021 | +2.6% | +4.2% | +0.3% | |
| Q4 2020 | -11.8% | -13.2% | -15.8% | |
| Q3 2020 | -1.0% | +4.5% | +11.6% | |
| Q2 2020 | +3.0% | +0.6% | -22.1% | |
| Q1 2020 | +7.7% | +9.0% | +22.5% | |
| Q4 2019 | +1.9% | -0.9% | -31.9% | |
| Q3 2019 | +14.8% | +18.6% | +22.5% | |
| Q2 2019 | +3.3% | -0.6% | -0.7% | |
| Q1 2019 | -0.3% | -4.1% | -43.2% | |
| Q4 2018 | -9.6% | -6.0% | -13.7% | |
| Q3 2018 | +13.1% | +15.6% | +7.8% | |
| Q2 2018 | -7.1% | -2.5% | -4.0% | |
| Q1 2018 | -4.1% | +1.6% | +17.7% | |
| Q4 2017 | -10.7% | -11.2% | -8.0% | |
| Q3 2017 | -18.7% | -16.6% | +8.8% | |
| Q2 2017 | -34.1% | -16.2% | -39.4% | |
| Q1 2017 | +1.7% | +1.3% | -3.6% | |
| Q4 2016 | +8.4% | +9.4% | +6.7% | |
| Q3 2016 | -7.2% | -6.0% | -10.5% | |
| Q2 2016 | +1.2% | -6.2% | -8.8% | |
| Q1 2016 | +5.2% | +1.7% | +10.8% | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -5.1% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +0.1% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q2 2014 | -1.6% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -1.5% | — | — | |
| Q2 2013 | -2.0% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | -3.3% | — | — | |
| Q1 2012 | -5.4% | — | — | |
| Q4 2011 | +2.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q2 2011 | +1.9% | — | — | |
| Q1 2011 | +5.6% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | +0.3% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | +1.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -1.4% | — | — | |
| Q3 2009 | -1.4% | — | — | |
| Q2 2008 | -0.8% | — | — | |
| Q2 2009 | -0.8% | — | — | |
| Q1 2009 | -0.6% | — | — | |
| Q1 2008 | -0.6% | — | — | |
| Q4 2008 | -0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro